Abstract:Background Proliferating cell nuclear antigen (PCNA) is essential for DNA replication and repair, cell growth, and survival. PCNA also enhances androgen receptor (AR) signaling in prostate cancer (PC) cells. We identified a PCNA interaction protein (PIP) box at the N‐terminal domain of AR and developed a small peptide PCNA inhibitor R9‐AR‐PIP containing AR PIP‐box. We also identified a series of small molecule PCNA inhibitors (PCNA‐Is) that bind directly to PCNA and interrupt PCNA functions. The present study investigated the effects of the PCNA inhibitors on the sensitivity of PC cells to X‐ray radiation. Methods The effects of targeting PCNA on radio sensitivity of PC cells were investigated in four lines of castration‐resistant PC (CRPC) cells with different AR expression statuses. The cells were treated with the PCNA inhibitors and X‐ray radiation alone or in combination. The effects of the treatment on expression of AR target genes, DNA damage response, DNA damage, homologous recombination repair (HRR), and cytotoxicity were evaluated. Results We found that the androgen response element (ARE) occupancy of the DNA damage response gene PARP1 by AR is significantly attenuated by PCNA‐I1S or R9‐AR‐PIP combined with X‐ray radiation, while X‐ray radiation alone does not enhance the ARE occupancy. PCNA‐I1S or R9‐AR‐PIP alone significantly inhibits occupancy of the AR‐occupied regions (AROR) in PRKDC and XRCC2 genes. R9‐AR‐PIP and PCNA‐I1S inhibit expression of AR‐Vs target gene cyclin A2 and show the additive effects with radiation in AR‐positive CRPC cells. Targeting PCNA by PCNA‐I1S and R9‐AR‐PIP downregulates expression of DNA damage response genes EXO1, Rad54L, Rad51, and/or PARP1 and shows the additive effects with radiation as compared with their respective controls in AR‐positive CRPC LNCaP‐AI, 22Rv1, and R1‐D567 cells, but not in AR‐negative PC‐3 cells. R9‐AR‐PIP and PCNA‐I1S elevate the levels of phospho‐DNA‐PKcs(S2056) and γH2AX, indicating DNA damage in response to radiation in AR‐positive cells. The HRR is significantly attenuated by PCNA inhibitors PCNA‐I1S, R9‐AR‐PIP, and T2AA in all four CRPC cells examined, and inhibited by Enzalutamide (Enz) only in 22RV1 cells. The cytotoxicity induced by X‐ray radiation in androgen‐dependent LNCaP cells is enhanced by Enz and a lower concentration of R9‐AR‐PIP in the colony formation assay. R9‐AR‐PIP at higher concentration reduces the colony formation and has an additive effect with X‐ray radiation in all AR expressing cells, regardless of AR‐FL and AR‐Vs, but does not significantly alter the colony formation in AR‐negative PC‐3 cells. PCNA‐I1S attenuates colony formation and has an additive effect with ionizing radiation in all four CRPC cells, regardless of AR expression status. Conclusion These data provide a strong rationale for the therapy studies using PCNA‐I1S or R9‐AR‐PIP in combination with X‐ray radiation against CRPC tumors in preclinical models.

The alkylphospholipid, perifosine, radiosensitizes prostate cancer cells both in vitro and in vivo

Combined Perifosine (Pi3k/Akt Inhibitor) And Radiotherapy For Prostate Cancer

Perifosine inhibits S6K1–Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency

The Alkylphospholipid Perifosine Induces Apoptosis of Human Lung Cancer Cells Requiring Inhibition of Akt and Activation of the Extrinsic Apoptotic Pathway

A Novel UCHL3 Inhibitor, Perifosine, Enhances PARP Inhibitor Cytotoxicity Through Inhibition of Homologous Recombination-Mediated DNA Double Strand Break Repair

Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3β in NSCLC cells.

Therapeutic potential of the Akt inhibitor perifosine in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) for metastatic head and neck cancer.

Radiofrequency Heat-Enhanced Direct Intratumoral Chemotherapy for Prostate Cancer

Inhibition of Both EGFR and IGF1R Sensitized Prostate Cancer Cells to Radiation by Synergistic Suppression of DNA Homologous Recombination Repair

Combination Therapy With The Histone Deacetylase Inhibitor Lbh589 And Radiation Is An Effective Regimen For Prostate Cancer Cells

Anticancer mechanisms and clinical application of alkylphospholipids

Perfluorocarbon Nanodroplets Stabilized with Cisplatin-Prodrug-constructed Lipids Enable Efficient Tumor Oxygenation and Chemo-Radiotherapy of Cancer.

Enhancing Effects of Olaparib by Alpha- and Beta-Emitting Radionuclides, X-Rays, and Ultraviolet A Light in Combination with Ortho-IodoHoechst in a Prostate Cancer Cell Model

Combined Anti-Cancer Effects of Platycodin D and Sorafenib on Androgen-Independent and PTEN-Deficient Prostate Cancer

NVP-BEZ235, Dual Phosphatidylinositol 3-Kinase/mammalian Target of Rapamycin Inhibitor, Prominently Enhances Radiosensitivity of Prostate Cancer Cell Line PC-3

The Short Chain Cell-Permeable Ceramide (C6) Restores Cell Apoptosis and Perifosine Sensitivity in Cultured Glioblastoma Cells

Pretargeted radiotherapy and synergistic treatment of metastatic, castration-resistant prostate cancer using cross-linked, PSMA-targeted lipoic acid nanoparticles

Targeting proliferating cell nuclear antigen enhances ionizing radiation‐induced cytotoxicity in prostate cancer cells

Enhancement of Radiotherapy Efficacy by Pleiotropic Liposomes Encapsulated Paclitaxel and Perfluorotributylamine.

Redox-responsive nanoparticles enhance radiation therapy by altering multifaceted radio-resistance mechanisms in human castration-resistant prostate cancer cells and xenografts

Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53- Deficient Prostate Cancer to Radiation